| Cancer Progression |
Migration/Invasion |
“ON” = Enhances “OFF” = Inhibits |
IGF1R, EGFR, Multi-receptor* |
5,9,26-28 |
| |
Stemness |
Not examined |
— |
29 |
| |
Chemoresistance |
Not examined |
— |
30 |
| |
Tumor-Stroma Interactions |
Not examined |
PDGFR, TGFβR, CXCR4 |
31 |
| |
Tumor angiogenesis |
Not examined |
VEGFR |
32 |
| Organ Fibrosis (Liver) |
Myofibroblast transdifferentiation, collagen production, chemotaxis, mitosis, anti-apoptotic signaling |
“ON” = Enhances “OFF” = Inhibits |
PDGFR, CCR1, TGFβR |
18 |
| Dermal Wound Healing |
Wound closure |
“ON” = Enhances “OFF” = Inhibits |
Multi-receptor* |
9 |
| Nephrotic Syndrome |
Podocyte survival after glomerular injury |
“ON” = Enhances survival “OFF” = Inhibits survival |
VEGFR |
14 |
| Disorders of Blood Vessels |
Neonatal vascular development; Pathologic neovascularization; vein repair; vein graft |
Not examined |
PDGF, Angiotensin II, VEGF |
33-35 |
| Neuronal Plasticity, Memory formation |
Synaptic plasticity |
Not examined |
NMDA |
36 |
